BCYC — BICYCLE THERAPEUTICS PLC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1761612 ·
Last close
$4.33
Market Cap
$218.12M
52W High
$4.74
52W Low
$3.74
ADV30
305,584
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 629,000 | — | -54,628,000 | -50,333,000 | 606,578,000 | 510,052,000 | 96,323,000 |
| Mar 2026 | 887,000 | — | -65,589,000 | -60,825,000 | 652,396,000 | 559,474,000 | 98,076,000 |
| Dec 2025 | 47,955,000 | — | -24,657,000 | -20,154,000 | 717,597,000 | 628,110,000 | 107,620,000 |
| Sep 2025 | 11,734,000 | — | -65,709,000 | -59,100,000 | 763,954,000 | 648,325,000 | 145,475,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-206,050,000
Investing CF
$-2,226,000
Financing CF
$-149,000
CapEx
$-2,226,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.73
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,010,909,000
Inventory
—
Receivables
$47,419,000
ST Investments
—
EBIT TTM
$-188,487,000
Pretax Income TTM
$-188,680,000
Interest Exp TTM
$193,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$61,205,000
EBITDA
$-200,812,000
Free Cash Flow
$-99,822,128
Enterprise Value
$-192,321,872
Total Cash
$510,052,000
Total Debt
$14,661,000
Shares Out
50,373,281
Trailing EPS
$-2.72
Book Value
$7.31
ROE
-32.3%
ROA
-17.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 72,586,000 | -247,718,000 | -218,960,000 | 717,597,000 | 107,620,000 | — | -249,675,000 |
| Dec 2024 | 35,275,000 | -209,153,000 | -169,031,000 | 956,868,000 | 163,808,000 | — | -164,724,000 |
| Dec 2023 | 26,976,000 | -189,946,000 | -180,664,000 | 595,344,000 | 224,412,000 | — | -60,628,000 |
| Dec 2022 | 14,463,000 | -116,653,000 | -112,717,000 | 410,609,000 | 139,826,000 | — | -86,111,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.22
Max Pain — expiry 2026-09-18
max pain strike: $5.00 · spot: $4.39 · call oi: 1,566 · put oi: 3,793
Expected Move to 2026-09-18:
±$0.68
(15.38%) —
implied range
$3.71 –
$5.06
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NBP | NovaBridge Biosciences | $218.58M | $1.89 | — |
| PEPG | PepGen Inc. | $220.94M | $3.19 | — |
| NGEN | NERVGEN PHARMA CORP. | $215.05M | $2.00 | — |
| ORGO | Organogenesis Holdings Inc. | $214.89M | $1.67 | — |
| KROS | Keros Therapeutics, Inc. | $213.74M | $10.78 | — |
News headlines (Yahoo Finance, 1h cache)
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
2026-06-02 15:08 · Yahoo
Morgan Stanley Updates Bicycle Therapeutics plc (BCYC) Outlook Amid Pipeline Refocus
2026-04-17 13:58 · Yahoo
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
2026-04-16 13:55 · Yahoo
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
2026-07-30 11:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading
2026-04-16 15:05 · Yahoo
RBC Capital Lowers its Price Target on Bicycle Therapeutics plc (BCYC) to $7 from $11
2026-04-04 12:16 · Yahoo
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
2026-03-24 13:35 · Yahoo
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-03-23 13:35 · Yahoo
Bicycle Therapeutics (BCYC) Appoints Travis Thompson as CFO Following Leadership Transitions
2026-03-14 10:21 · Yahoo
European Equities Traded in the US as American Depositary Receipts Start Week Lower
2026-02-23 16:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.